

A prospective randomised placebo controlled trial of treatment for fibrosing alveolitis in scleroderma

Submission date 15/07/2002	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 15/07/2002	Overall study status Completed	☐ Protocol
Last Edited 03/10/2007	Condition category Musculoskeletal Diseases	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof RM duBois

Contact details
Royal Brompton Hospital
Sydney Street
London
United Kingdom
SW3 6MP
+44 (0)20 7351 8327
r.dubois@rbh.nthames.nhs.uk

Additional identifiers

Protocol serial number
D0554

Study information

Scientific Title

Acronym

FAST study

Study objectives

Does routine treatment with cyclophosphamide, azathioprine and prednisolone improve outcomes in fibrosing alveolitis associated with scleroderma?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Fibrosing alveolitis in scleroderma

Interventions

Intravenous cyclophosphamide plus prednisolone for 6 months followed by azathioprine for 2.5 years or placebo for all drugs

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Cyclophosphamide, azathioprine and prednisolone

Primary outcome(s)

1. Change in percent predicted Forced Vital Capacity (FVC)
2. Change in single-breath diffusing capacity for carbon monoxide (DLCO)

Key secondary outcome(s)

1. Changes in appearance on high-resolution computed tomography
2. Change in dyspnoea scores

Completion date

31/10/2003

Eligibility

Key inclusion criteria

1. Aged 18 - 75 years
2. American College of Rheumatology (ACR) criteria for scleroderma
3. Evidence for fibrosing alveolitis - High Resolution Computed Tomography (HRCT) or surgical biopsy

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/10/1998

Date of final enrolment

31/10/2003

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Royal Brompton Hospital

London

United Kingdom

SW3 6MP

Sponsor information

Organisation

Arthritis Research Campaign (ARC) (UK)

ROR

<https://ror.org/02jkpm469>

Funder(s)

Funder type

Charity

Funder Name

Arthritis Research Campaign (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/12/2006		Yes	No